LON:STX Shield Therapeutics (STX) Share Price, News & Analysis GBX 3.05 +0.05 (+1.67%) As of 11:32 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsNews and Trends About Shield Therapeutics Stock (LON:STX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Shield Therapeutics alerts:Sign Up Key Stats Today's Range 2.92▼ 3.2050-Day Range 3▼ 5.9652-Week Range 2.92▼ 12.50Volume1.50 million shsAverage Volume2.47 million shsMarket Capitalization£32.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s. Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics. Read More Receive STX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STX Stock News HeadlinesShield Therapeutics plc Provides Earnings Guidance for the Year 2026November 4, 2026 | marketscreener.comMShield Therapeutics Reports 5% Rise in US ACCRUFeR Revenue to $10.8 Million but Revises FY2026 Profit OutlookNovember 3, 2026 | uk.finance.yahoo.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 17 at 1:00 AM | Behind the Markets (Ad)Shield Therapeutics loses profitability target as Medicaid pressures offset prescription growthNovember 3, 2026 | finance.yahoo.comShield Therapeutics updates total voting rights and share capitalOctober 3, 2026 | theglobeandmail.comShield Therapeutics cuts H1 loss as ACCRUFeR growth drives revenue higherAugust 20, 2026 | uk.finance.yahoo.comShield Therapeutics jumps 11% as losses narrow and profitability target heldAugust 20, 2026 | finance.yahoo.comShield Therapeutics shares slip after interims, small-cap pharma says its still 'on-track'July 30, 2026 | uk.finance.yahoo.comSee More Headlines STX Stock Analysis - Frequently Asked Questions How have STX shares performed this year? Shield Therapeutics' stock was trading at GBX 10 at the beginning of 2026. Since then, STX shares have decreased by 69.5% and is now trading at GBX 3.05. How were Shield Therapeutics' earnings last quarter? Shield Therapeutics plc (LON:STX) released its quarterly earnings data on Thursday, April, 24th. The company reported GBX (3) earnings per share (EPS) for the quarter. Shield Therapeutics had a negative net margin of 17.76% and a positive trailing twelve-month return on equity of 64.57%. How do I buy shares of Shield Therapeutics? Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include Seeing Machines (SEE), Allogene Therapeutics (ALLO), Atlantic Lithium (ALL), Beeks Financial Cloud Group (BKS), Currys (CURY), Fresnillo (FRES) and ITM Power (ITM). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolLON:STX CIKN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500FaxN/AEmployees40,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£36.28 million Net Margins-17.76% Pretax MarginN/A Return on Equity64.57% Return on Assets-47.85% Debt Debt-to-Equity Ratio-146.28 Current Ratio0.75 Quick Ratio2.16 Sales & Book Value Annual Sales£58.63 million Price / Sales0.56 Cash FlowGBX 0.48 per share Price / Cash Flow6.36 Book ValueGBX 0.05 per share Price / Book55.73Miscellaneous Outstanding Shares1,074,194,000Free FloatN/AMarket Cap£32.76 million OptionableNot Optionable Beta1.77 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (LON:STX) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shield Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.